Lilly adds to buyout streak with $1.5B purchase of startup Calytrix
BioPharma DiveBen FidlerNovember 16, 2026
Lilly s 15th announced company acquisition this year by far the most in the biopharmaceutical sector centers around a precision therapy for rare blood disorders known as myeloproliferative neoplasms.
